The short version of albumin conjugate fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-29 and is reviewed periodically as new material appears.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
=== Competing reactions === The most common side reactivity associated with the Stille reaction is homocoupling of the stannane reagents to form an R2-R2 dimer. It is believed to proceed through two possible mechanisms. First, reaction of two equivalents of organostannane with the Pd(II) precatalyst will yield the homocoupled product after reductive elimination. Second, the Pd(0) catalyst can undergo a radical process to yield the dimer. The organostannane reagent used is traditionally tetravalent at tin, normally consisting of the sp2-hybridized group to be transferred and three "non-transferable" alkyl groups. As seen above, alkyl groups are normally the slowest at migrating onto the palladium catalyst.
In 1884, Svante Arrhenius attributed the properties of acidity to hydrogen cations (H+), later described as protons or hydrons. An Arrhenius acid is a substance that, when added to water, increases the concentration of H+ ions in the water. Chemists often write H+(aq) and refer to the hydrogen cation when describing acid–base reactions but the free hydrogen nucleus, a proton, does not exist alone in water, it exists as the hydronium ion (H3O+) or other forms (H5O2+, H9O4+). Thus, an Arrhenius acid can also be described as a substance that increases the concentration of hydronium ions when added to water. Examples include molecular substances such as hydrogen chloride and acetic acid. An Arrhenius base, on the other hand, is a substance that increases the concentration of hydroxide (OH−) ions when dissolved in water. This decreases the concentration of hydronium because the ions react to form H2O molecules:
In terms of dosage equivalence, norethisterone and NETA are typically used at respective dosages of 0.35 mg/day and 0.6 mg/day as progestogen-only contraceptives, and at respective dosages of 0.5–1 mg/day and 1–1.5 mg/day in combination with ethinylestradiol in combined oral contraceptives. Conversely, the two drugs have been used at about the same dosages in menopausal hormone therapy for the treatment of menopausal symptoms. NETA is of about 12% higher molecular weight than norethisterone due to the presence of its C17β acetate ester. Micronization of NETA has been found to increase its potency by several-fold in animals and women. The endometrial transformation dosage of micronized NETA per cycle is 12 to 14 mg, whereas that for non-micronized NETA is 30 to 60 mg.
In 1969, after completing her medical training, she became a lecturer at the Department of Bacteriology and Immunology in Glasgow's Western Infirmary teaching hospital. While working at the hospital she carried out research on the role of intra-epithelial lymphocytes in intestinal immunity, receiving her PhD in 1974. In 1975, she was appointed as a senior lecturer at the University of Edinburgh, also becoming a consultant at the Gastrointestinal Unit at the Western General Hospital in Edinburgh. In 1987 she was appointed to a personal professorship in gastroenterology. From 1991 to 1994 she was head of the Department of Medicine at the university. She published more than 250 papers in peer-reviewed academic journals, published three books and contributed chapters to many other books. Her research provided new insights into the mechanisms responsible for Crohn's and coeliac diseases which led to significant advances in the therapy of these conditions. She also carried out significant research on oral tolerance. She served on the Committee on Safety of Medicines, the Medical Research Council Gene Therapy Advisory Board, and the Spongiform Encephalopathy Advisory Committee. At the time of her death she was president of the Society for Mucosal Immunology. She was a consultant providing advice and training to the International Centre for Diarrhoeal Disease Research in Bangladesh.
Sources: en.wikipedia.org
In molecular biology, subcloning is a technique used to move a particular DNA sequence from a parent vector to a destination vector. Subcloning is not to be confused with molecular cloning, a related technique.
The King (from 1952, the Queen of South Africa) was represented by the Governor-General. The Senate consisted of senators nominated by the four provinces, and by the Governor-General, initially for a period of ten years. The number of senators was changed from time to time. The Senate was chaired by a President of the Senate chosen by the senators from among themselves. The House of Assembly consisted of members who were directly elected by the voters. Each MP represented an electoral district (constituency), and most of them were elected on the basis of their political party. The number of constituencies and parliamentary seats was increased from time to time, in line with increases in the population. The House was chaired by a Speaker chosen by the MPs from among themselves. Only white men could be senators or MPs. The franchise (right to vote) was originally granted to white men in all four provinces, to black men in the Cape Province and Natal, and to Coloured men in the Cape Province – in all cases, the minimum age was 21 years. The composition of Parliament was changed by constitutional amendments from time to time:
=== Pregnancy === When given in the second or third trimesters of pregnancy, no artesunate-related adverse pregnancy outcomes have been reported. However, there is insufficient evidence regarding the safety of artesunate use in the first trimester of pregnancy. The WHO recommends that artesunate use for severe malaria in the first trimester should be based on the individual risks versus benefits. In absence of other viable treatment options, artesunate may be used.
semi-crystalline: high crystallinity: PA46 and PA66; low crystallinity: PAMXD6 made from m-xylylenediamine and adipic acid; amorphous: PA6I made from hexamethylenediamine and isophthalic acid. According to this classification, PA66, for example, is an aliphatic semi-crystalline homopolyamide.
The 'Dunkin' Donut' with a handle fashioned on it was discontinued in 2003 (except in Singapore) because it was hand-cut and uneconomical compared to machine-cut doughnuts. In 2004, the company's headquarters were relocated to Canton, Massachusetts. In December 2005, Dunkin' Donuts and Baskin-Robbins (by then, operating under the name Dunkin' Brands) were sold to a private equity consortium of Bain Capital, Carlyle Group, and Thomas H. Lee Partners for $2.4 billion. By 2010, Dunkin' Donuts' global sales were $6 billion. In June 2013, Dunkin' Donuts unveiled a new store design, the brand's first in almost seven years. The Dunkin' Donuts location in Natick, Massachusetts launched a program to test the concept of curbside pickup in December 2016. In January 2018, Dunkin' Donuts started opening new concept locations, beginning in Quincy, featuring modern decor, cold beverages on tap and a single-cup brewing machine, more packaged takeout options, and dedicated pick-up lines for mobile ordering inside and in the drive-thru. The concept was described as being part of a shift towards becoming an "on-the-go, beverage-led brand". In addition, the location, as well as others, began to trial signage referring to the chain as simply "Dunkin'"—removing "Donuts" from the name. In February 2018, Dunkin' announced plans to phase out polystyrene foam cups globally for environmental purposes by April 2020. In July 2018, Dave Hoffmann took over from Nigel Travis to become the CEO.
Sources: en.wikipedia.org
Consumption of breakfast cereal is under preliminary research for the potential to improve nutrition and affect chronic diseases. Regular breakfast cereal consumption is associated with less risk of being overweight or obese and high-fiber breakfast cereals are associated with a lower risk of diabetes. Fortified breakfast cereals with iron can be an effective option to reduce risk of anemia in children.
Since 1971, SI defined the "amount of substance" as a separate dimension of measurement. Until 2019, the mole was defined as the amount of substance that has as many constituent particles as there are atoms in 12 grams of carbon-12, with the dalton defined as +1/12 of the mass of a carbon-12 atom. Thus, during that period, the numerical value of the molar mass of a substance expressed in g/mol was exactly equal to the numerical value of the average mass of an entity (atom, molecule, formula unit) of the substance expressed in daltons. Since 2019, the mole has been redefined in the SI as the amount of any substance containing exactly 6.02214076×1023 entities, fixing the numerical value of the Avogadro constant NA when expressed in the unit mol−1, but because the dalton is still defined in terms of the experimentally determined mass of a carbon-12 atom, the numerical equivalence between the molar mass of a substance and the average mass of an entity of the substance is now only approximate, but equality may still be assumed with high accuracy—(the relative discrepancy is only of order 10–9, i.e. within a part per billion).
She has given a great deal of thought to how women are taught to act as they grow up and how that may impact their career decisions. In an interview in 2004, Osborn said, "In deciding whether to accept new challenges a remark by Diane Britten some years ago in The Times has proved very helpful: "When asked to do something women tend to say `Why me?' Men say `Why not me?' I have learned to say `Why not me?''' Summing up her advice to those in charge of sciences in universities and industry, she said in 2012, "Above all one has to get the argument across that it is wasteful, expensive and unfair to educate and train large numbers of woman scientists and then not use their talents in the job market or provide equal access to the top jobs."
== History == Xylazine was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Leverkusen, West Germany. In human trials xylazine was found to depress the central nervous system leading to the discontinuation of further research for its use in humans and it was instead marketed as a veterinary sedative, starting in the late 1960s. Xylazine proved popular and in the 1970s became one of the most common large animal sedatives. Xylazine's muscle relaxant effect inhibits the transmission of neural impulses in the central nervous system. In 1981 a study discovered that the cause sedation was due to xylazine's effect on the α2-adrenergic receptor. This led to the development of other α2-adrenergic receptor agonists such as detomidine, medetomidine, dexmedetomidine, and romifidine. In the United States, xylazine was approved by the FDA only for veterinary use as a sedative, analgesic, and muscle relaxant in dogs, cats, horses, elk, fallow deer, mule deer, sika deer, and white-tailed deer. In scientific research using animal experiments, xylazine is a component of the most common anesthetic, ketamine-xylazine (see: Rodent cocktail), to anesthetize rats, mice, hamsters, and guinea pigs. Xylazine has not previously been a controlled substance; however, due to illicit abuse, legislative restrictions have been proposed in multiple countries. Xylazine was made a class C drug in the UK on 15 January 2025.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.